Literature DB >> 21454878

The rationale for using hydroxycarbamide in the treatment of sickle cell disease.

David C Rees.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21454878      PMCID： PMC3069221          DOI： 10.3324/haematol.2011.041988

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Authors:  Martin H Steinberg; Franca Barton; Oswaldo Castro; Charles H Pegelow; Samir K Ballas; Abdullah Kutlar; Eugene Orringer; Rita Bellevue; Nancy Olivieri; James Eckman; Mala Varma; Gloria Ramirez; Brian Adler; Wally Smith; Timothy Carlos; Kenneth Ataga; Laura DeCastro; Carolyn Bigelow; Yogen Saunthararajah; Margaret Telfer; Elliott Vichinsky; Susan Claster; Susan Shurin; Kenneth Bridges; Myron Waclawiw; Duane Bonds; Michael Terrin
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

2.  Metabolic and therapeutic effects of hydroxyurea in chronic myelogenous leukemia.

Authors:  B J Kennedy; J W Yarbro
Journal:  Trans Assoc Am Physicians       Date:  1965

3.  Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex.

Authors:  S Charache; G Dover; K Smith; C C Talbot; M Moyer; S Boyer
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

4.  Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin.

Authors:  Andreia A Canalli; Renata F Proença; Carla F Franco-Penteado; Fabiola Traina; Tatiana M Sakamoto; Sara T O Saad; Nicola Conran; Fernando F Costa
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

Review 5.  Sickle-cell disease.

Authors:  David C Rees; Thomas N Williams; Mark T Gladwin
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

6.  A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy.

Authors:  K R Bridges; G D Barabino; C Brugnara; M R Cho; G W Christoph; G Dover; B M Ewenstein; D E Golan; C R Guttmann; J Hofrichter; R V Mulkern; B Zhang; W A Eaton
Journal:  Blood       Date:  1996-12-15       Impact factor: 22.113

7.  Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.

Authors:  Vladan P Cokic; Reginald D Smith; Bojana B Beleslin-Cokic; Joyce M Njoroge; Jeffery L Miller; Mark T Gladwin; Alan N Schechter
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

8.  Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.

Authors:  A Ferster; C Vermylen; G Cornu; M Buyse; F Corazza; C Devalck; P Fondu; M Toppet; E Sariban
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

9.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

10.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.

Authors:  O S Platt; S H Orkin; G Dover; G P Beardsley; B Miller; D G Nathan
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808
View more
  17 in total

1.  The rationale for using hydroxycarbamide in the treatment of sickle cell disease" (Haematologica 2011;96:488-491). Reply.

Authors:  Simeon Pollack
Journal:  Haematologica       Date:  2011-06       Impact factor: 9.941

2.  Generation of a genomic reporter assay system for analysis of γ- and β-globin gene regulation.

Authors:  Kasey S K Chan; Jian Xu; Hady Wardan; Bradley McColl; Stuart Orkin; Jim Vadolas
Journal:  FASEB J       Date:  2012-01-20       Impact factor: 5.191

3.  Effects of 5'-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective.

Authors:  Amber Ilyas; Zehra Hashim; Shamshad Zarina
Journal:  Mol Cell Biochem       Date:  2015-04-09       Impact factor: 3.396

Review 4.  Management of sickle cell disease in the community.

Authors:  Valentine Brousse; Julie Makani; David C Rees
Journal:  BMJ       Date:  2014-03-10

Review 5.  Hydroxyurea therapy for sickle cell anemia.

Authors:  Patrick T McGann; Russell E Ware
Journal:  Expert Opin Drug Saf       Date:  2015-09-14       Impact factor: 4.250

Review 6.  Clinical management of sickle cell liver disease in children and young adults.

Authors:  Eirini Kyrana; David Rees; Florence Lacaille; Emer Fitzpatrick; Mark Davenport; Nigel Heaton; Sue Height; Marianne Samyn; Fulvio Mavilio; Valentine Brousse; Abid Suddle; Subarna Chakravorty; Anita Verma; Girish Gupte; Marki Velangi; Baba Inusa; Emma Drasar; Nedim Hadzic; Tassos Grammatikopoulos; Jonathan Hind; Maesha Deheragoda; Maria Sellars; Anil Dhawan
Journal:  Arch Dis Child       Date:  2020-11-11       Impact factor: 3.791

7.  Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study.

Authors:  Susumu Inoue; Gergana Kodjebacheva; Tammy Scherrer; Gary Rice; Matthew Grigorian; Jeremy Blankenship; Nkechi Onwuzurike
Journal:  Int J Hematol       Date:  2016-05-25       Impact factor: 2.490

8.  Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance.

Authors:  Ademola Samson Adewoyin; Omokiniovo Sunday Oghuvwu; Omolade Augustina Awodu
Journal:  Afr Health Sci       Date:  2017-03       Impact factor: 0.927

9.  Nocturnal enuresis and K+ transport in red blood cells from patients with sickle cell anemia.

Authors:  Sanjay Tewari; David C Rees; Anke Hannemann; Oluwabukola T Gbotosho; Halima W M Al Balushi; John S Gibson
Journal:  Haematologica       Date:  2016-09-01       Impact factor: 9.941

10.  Effects of 5-hydroxymethyl-2-furfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease.

Authors:  Anke Hannemann; Urszula M Cytlak; David C Rees; Sanjay Tewari; John S Gibson
Journal:  J Physiol       Date:  2014-07-11       Impact factor: 5.182
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.